Abstract
Long-term sequelae of severe acute respiratory coronavirus-2 (SARS-CoV-2) infection may include an increased incidence of diabetes. Our objective was to describe the temporal relationship between new diagnoses of diabetes mellitus and SARS-CoV-2 infection in a nationally representative database. There appears to be a sharp increase in diabetes diagnoses in the 30 days surrounding SARS-CoV-2 infection, followed by a decrease in new diagnoses in the post-acute period, up to 360 days after infection. These results underscore the need for further investigation, as understanding the timing of new diabetes onset after COVID-19 has implications regarding potential etiology and screening and treatment strategies.
Competing Interest Statement
CTB is funded by the National Institute of Digestive Diabetes and Kidney Diseases K23DK124654. JST is funded by K23DK116935 National Institutes of Health (NIH). TS receives investigator-initiated research funding and support as Principal Investigator (R01 AG056479) from the National Institute on Aging (NIA) and as Co-Investigator (R01 HL118255 R01MD011680) NIH. TS also receives salary support as Director of Comparative Effectiveness Research (CER) NC TraCS Institute UNC (UL1TR002489) the Center for Pharmacoepidemiology (current members: GlaxoSmithKline UCB BioSciences Takeda AbbVie Boehringer Ingelheim) from pharmaceutical companies (Novo Nordisk) and from a generous contribution from Dr. Nancy A. Dreyer to the Department of Epidemiology University of North Carolina at Chapel Hill. TS does not accept personal compensation of any kind from any pharmaceutical company and owns stock in Novartis Roche and Novo Nordis. JBB contracted consulting fees and travel support for contracted activities are paid to the University of North Carolina by Adocia AstraZeneca Eli Lilly Intarcia Therapeutics MannKind Novo Nordisk Sanofi Senseonics and vTv Therapeutics. JBB reports grant support from AstraZeneca Dexcom Eli Lilly Intarcia Therapeutics Johnson & Johnson Lexicon NovaTarg Novo Nordisk Sanofi Theracos Tolerion and vTv Therapeutics. JBB has received fees for consultation from Anji Pharmaceuticals AstraZeneca Boehringer Ingelheim Cirius Therapeutics Inc Eli Lilly Fortress Biotech Janssen Mellitus Health Moderna Pendulum Therapeutics Praetego Stability Health and Zealand Pharma. JBB holds stock/options in Mellitus Health Pendulum Therapeutics PhaseBio Praetego and Stability Health. JBB is supported by grants from the National Institutes of Health Patient Centered Outcomes Research Institute Juvenile Diabetes Research Foundation International and the American Diabetes Association.
Funding Statement
This study was funded by: National Center for Advancing Translational Sciences (U24 TR002306); Clinical and Translational Science Institute, University of Minnesota (UL1TR002494); National Institute of Diabetes and Digestive and Kidney Diseases (K23DK124654, Recipient: Carolyn T Bramante, MD, MPH)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This analysis was approved by the University of Minnesota institutional review board (STUDY00011578), which provided a waiver of consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Reddy169{at}umn.edu; Bramante{at}umn.edu
hyeh1{at}jhmi.edu
Jena.Tronieri{at}pennmedicine.upenn.edu
sturmer{at}unc.edu
john_buse{at}med.unc.edu
JANE.REUSCH{at}cuanschutz.edu
joh06288{at}umn.edu
rachel.wong{at}stonybrookmedicine.edu; Richard.Moffitt{at}stonybrookmedicine.edu
kenneth.wilkins{at}nih.gov
jeremytech{at}gmail.com
Conflicts of Interest and Funding Information: Dr. Bramante is funded by the National Institute of Digestive, Diabetes, and Kidney Diseases K23DK124654; and Dr. Tronieri by K23DK116935 (JT), National Institutes of Health (NIH). TS receives investigator-initiated research funding and support as Principal Investigator (R01 AG056479) from the National Institute on Aging (NIA), and as Co-Investigator (R01 HL118255, R01MD011680), NIH. He also receives salary support as Director of Comparative Effectiveness Research (CER), NC TraCS Institute, UNC (UL1TR002489), the Center for Pharmacoepidemiology (current members: GlaxoSmithKline, UCB BioSciences, Takeda, AbbVie, Boehringer Ingelheim), from pharmaceutical companies (Novo Nordisk), and from a generous contribution from Dr. Nancy A. Dreyer to the Department of Epidemiology, University of North Carolina at Chapel Hill.
Disclosures: J.B.B.’s contracted consulting fees and travel support for contracted activities are paid to the University of North Carolina by Adocia, AstraZeneca, Eli Lilly, Intarcia Therapeutics, MannKind, Novo Nordisk, Sanofi, Senseonics, and vTv Therapeutics; he reports grant support from AstraZeneca, Dexcom, Eli Lilly, Intarcia Therapeutics, Johnson & Johnson, Lexicon, NovaTarg, Novo Nordisk, Sanofi, Theracos, Tolerion, and vTv Therapeutics; he has received fees for consultation from Anji Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Cirius Therapeutics Inc, Eli Lilly, Fortress Biotech, Janssen, Mellitus Health, Moderna, Pendulum Therapeutics, Praetego, Stability Health, and Zealand Pharma; he holds stock/options in Mellitus Health, Pendulum Therapeutics, PhaseBio, Praetego, and Stability Health; and he is supported by grants from the National Institutes of Health, Patient Centered Outcomes Research Institute, Juvenile Diabetes Research Foundation International and the American Diabetes Association. Dr. Stürmer does not accept personal compensation of any kind from any pharmaceutical company. He owns stock in Novartis, Roche, and Novo Nordis.
Data Availability
All data produced in the present work are contained in the manuscript and supplemental materials.
